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Tab. 1: Results, 20112 Transferred to the entire birth cohort, universal screening is able to reduce total costs from 13.35 million € to 2.89 million € from the Austrian societal perspective each year. Screening results in 665 QALYs gained and more than 161 LYs saved for the entire birth cohort.
Sensitivity Analysis
In the deterministic one-way sensitivity analyses (Figure 2 ), our results were robust to a wide range of plausible estimates of unit cost data. Cost savings persisted for the screening strategy in all variations of the sensitivity analyses. Unit costs of IgG exhibit a great influence on total costs (35 € -43.3 €) per child in the screening arm. The incremental costeffectiveness advantage for the screening strategy ranged between -16,026.44 € and -15,072 .41 €. Among cost components, indirect costs show a greater influence on total costs than direct costs.
Clinical Data
Seroprevalence, probabilities of symptoms (symptomatic and asymptomatic) in the screening arm derived from the nationwide database of the reference center (Medical University of Vienna). The no screening probabilities of symptoms were modeled in accordance with the Stillwaggon paper.
Resource Use and Costs
Data on the resource use of screening (IgG, IgM, amniocentesis (PCR), newborn-test, head ultrasound, blood test, fundoscopy, ECG), maternal and pediatric treatment (medication, dosage and treatment duration) derived from the nationwide database of the reference center. Data on the resource use of symptoms was collected in two steps. First, the medical resources were derived by literature (e.g. disease specific guidelines). In a second step this literature review was verified by experts. Direct medical costs derived from a number of publicly available sources like outpatient clinic catalogue as well as the DRG catalogue (LKF) and official price lists for the Austrian Health insurances funds. Indirect Cost represent statistical and published data as well as own calculations. When necessary, prices were adjusted to 2012 prices using the consumer price index.
Source: IPF own calculations 
Methods
We developed a two arm decision-analytic model. One arm of the model assessed the costs and consequences of no prevention, while the other one evaluated the screening. The study population included pregnant women and offspring screened and treated for toxoplasma infection. The average number of births was 76,547 and 50,000 pregnant women were susceptible to infection. The analysis focused on lifetime consequences of the connatal infection. This encompassed direct costs (screening, cost of illness, maternal and pediatric treatment), indirect costs (changed job situation of parents, human-capital of dead individuals, blindness and special schools), qualityadjusted-life-years (QALYs) and reduced expectation of life. Costs were presented per child and for the Austrian birth rate. Costs from published sources were used for 2012 from the societal perspective. QALYs, life-years (LYs) and costs were projected over a life-time horizon and discounted at 3% per anno.
Source: own developed [+] indicates that the subtree is not completely displayed. The content of the subtrees are the same as in the subtree above.
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Results
Without screening, the total discounted societal cost (direct and indirect) amounts to 174.43 € per child screened (calculations based on the 76,547 newborns). This strategy resulted in a discounted quality-adjusted life expectancy of 31.121 QALYs. The corresponding life expectancy without quality adjustment amounted to 31.128 life-years. 34.49 € out of the 37.72 € (total costs per child of the universal screening strategy) are screening and maternal treatment costs. 3.23 € accounts for follow up costs due to fetal disease. According to our calculations 5 pregnant women can be screened in order to treat one infected child. 
